A major UK clinical research project investigating the potential use of psilocybin for treatment-resistant depression has reached an important milestone. Oxford Health NHS Foundation Trust has announced that the final participant has completed their last study visit in the COMP006 clinical trial at its Clinical Research Facility.
The announcement, published on 2 November 2026, marks the completion of Oxford’s active involvement in this phase of the international research programme.
Oxford Health NHS Completes Its Part in COMP006 Study
The COMP006 study is part of an international Phase 3 clinical research programme evaluating COMP360, a synthetic formulation of psilocybin developed by Compass Pathways.
The research focuses on people living with treatment-resistant depression (TRD). This condition generally refers to depression that has not responded adequately to at least two different antidepressant treatments.
At the NIHR Clinical Research Facility: Oxford Health, researchers have supported participants through treatment sessions, follow-up assessments and longer-term monitoring since the study began in Oxford in 2024.
The treatment being investigated combines psilocybin with psychological support delivered as part of a structured clinical trial.
What Have Researchers Discovered So Far?
Although the full analysis is still ongoing, earlier interim findings have provided important information.
In February 2026, Compass Pathways reported a statistically significant reduction in depression symptom severity at six weeks among participants who received two 25mg doses of COMP360, compared with participants in the 1mg comparator group.
The company also reported ongoing discussions with the US Food and Drug Administration (FDA) regarding its regulatory submission process.
These findings are an important part of the continuing investigation, but further analysis is needed to understand the longer-term outcomes and overall safety profile.
What Happens Next?
With the final participant completing their visit in Oxford, the local research team has finished its active delivery phase of the study.
However, the wider international research programme is continuing. Researchers will analyse longer-term results and examine outcomes from later stages of the trial.
Any decisions about future medical use will depend on the complete clinical evidence and reviews by the relevant regulatory authorities.
Oxford Health has also indicated that its Clinical Research Facility plans to explore further studies involving novel treatments, including psychedelic-based research for different mental health conditions.
Why Is This Research Important?
Treatment-resistant depression remains a significant challenge for patients and healthcare professionals. Some people do not experience sufficient improvement with existing antidepressant treatments.
Research into alternative approaches, including psilocybin-assisted therapy, may help scientists better understand new possibilities for mental health treatment.
However, it is important to recognise that COMP360 remains an investigational treatment. Clinical trial findings should not be interpreted as proof that psilocybin is an established or approved treatment for depression.
Source and Further Reading
This news report is based on an announcement published by Oxford Health NHS Foundation Trust on 2 November 2026.
Read the original announcement:
About Psilocybin Pulse: Follow TrippingStore’s Psilocybin Pulse for updates on psychedelic research, clinical trials, neuroscience and developments in mental health research.
Editorial note: This article is intended for educational and research information only. It does not constitute medical advice or a recommendation to use psilocybin.
